Adragos Pharma has acquired Swiss-based aseptic fill-finish manufacturing expert, Baccinex.
The acquisition will provide Adragos with more than 20 years of experience in sterile fill-finish process development and manufacturing for both lyophilised and liquid injectables, significantly bolstering their capabilities in this area.
Baccinex operates from its GMP and FDA-certified facility, and specialises in supplying clinical trials, as well as small-to-medium scale commercial customers.
This acquisition follows Adragos' efforts to expand its global network as a contract development and manufacturing (CDMO) partner for the pharmaceutical industry.
Dr Ursula Bausch, founder and CEO of Baccinex, will remain in her position to ensure that operational continuity is maintained.
She will also continue on as a shareholder in the company post-acquisition.
Ursula commented: “Joining Adragos Pharma marks a new chapter for Baccinex. Our shared commitment to quality, innovation, and customer-centric solutions creates an exciting synergy that will enable us to deliver even greater value to our clients worldwide.”
Dr Andreas Raabe, founder and CEO of Adragos Pharma, commented: “The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilisation, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply."
"This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”
[Image credit: Marc Chatelain]